Published in final edited form as:

Mol Immunol. 2015 October ; 67(2 0 0): 131–141. doi:10.1016/j.molimm.2015.02.007.

Targeting FcRn for the modulation of antibody dynamics

E. Sally Ward^{a,b,c,*}, Siva Charan Devanaboyina^c, and Raimund J. Ober^{a,d}

^a Department of Molecular and Cellular Medicine, Texas A&M Health Science Center, College Station, TX 77843-1114, USA

^b Department of Microbial Pathogenesis and Immunology, Texas A&M Health Science Center, College Station, TX 77843-1114, USA

^c Department of Immunology, University of Texas Southwestern Medical Center, 6001 Forest Park Rd., Dallas, TX 75390-9093, USA

^d Department of Biomedical Engineering, Texas A&M University, College Station, TX 77843-3120, USA

Abstract

The MHC Class I-related receptor, FcRn, is a multitasking protein that transports its IgG ligand within and across cells of diverse origins. The role of this receptor as a global regulator of IgG homeostasis and transport, combined with knowledge of the molecular details of FcRn-IgG interactions, has led to opportunities to modulate the in vivo dynamics of antibodies and their antigens through protein engineering. Consequently, the generation of half-life extended antibodies has shown a rapid expansion over the past decade. Further, FcRn itself can be targeted by inhibitors to induce decreased levels of circulating IgGs, which could have applications in multiple clinical settings. The engineering of antibody-antigen interactions to reduce antibody-mediated buffering of soluble ligand has also developed into an active area of investigation, leading to novel antibody platforms designed to lead to more effective antigen clearance. Similarly, the target-mediated elimination of antibodies by internalizing, membrane bound antigens (receptors) can be decreased using novel engineering approaches. These strategies, combined with subcellular trafficking analyses of antibody/antigen/FcRn behavior in cells to predict in vivo behavior, have considerable promise for the production of next generation therapeutics and diagnostics.

Keywords

FcRn; IgG; pharmacokinetics; antibody engineering; therapeutic antibodies; pH-dependence

*Corresponding author: E. Sally Ward, Department of Molecular and Cellular Medicine, Texas A&M Health Science Center, Joe H. Reynolds Medical Sciences Building, Room 469, College Station, TX 77843-1114, USA. Tel.: +1 214 648 1260. sally.ward@medicine.tamhsc.edu. Siva.Devanaboyina@UTSouthwestern.edu. Raimund.ober@tamu.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1. Introduction

The function of the MHC Class I-related receptor, FcRn, as a transporter of antibody molecules of the immunoglobulin G (IgG) class within and across multiple cell types is well documented (Roopenian and Akilesh, 2007; Ward and Ober, 2009). Through this transport function, FcRn serves not only to transport antibodies across cellular barriers (Bitonti et al., 2004; Claypool et al., 2004; Dickinson et al., 1999; Firan et al., 2001; McCarthy et al., 2000; Spiekermann et al., 2002), but also to regulate the levels of antibodies in the body (Ghetie et al., 1996; Israel et al., 1996; Junghans and Anderson, 1996). In addition, FcRn binds and transports albumin (Chaudhury et al., 2003). The ability of FcRn to serve as a homeostatic regulator of IgG and albumin is essential for normal health, in addition to having implications for protein engineering directed towards modulating the pharmacokinetics of therapeutics and the dynamic behavior of endogenous antibodies. In the current review we will discuss the molecular and cellular aspects of FcRn activity, with a particular focus on its role in IgG homeostasis. How this knowledge can be exploited to modulate IgG dynamics in vivo will also be presented.

2. The molecular players of FcRn-IgG interactions

The residues at the CH2-CH3 domain interface of an IgG that mediate FcRn binding are well defined through site-directed mutagenesis and X-ray crystallographic analyses (Firan et al., 2001; Kim et al., 1999; Kim et al., 1994; Martin et al., 2001; Medesan et al., 1997; Raghavan et al., 1995; Shields et al., 2001). These studies have led to the identification of three IgG residues that are critical for binding (Ile253, His310 and His435). The residues are located at the CH2-CH3 domain interface of the IgG molecule and are either invariant (Ile253, His310) or present in the majority (His435) of human, rat and mouse IgGs (Deisenhofer, 1981; Kabat et al., 1991). By contrast with the high conservation of residues 253, 310 and 435, residue 436 (His in mouse IgG1, Tyr in human IgG1) shows higher variability across species and plays a more minor role in FcRn-IgG interactions (Medesan et al., 1997; Shields et al., 2001). Although His433 has been reported to contribute to FcRn-IgG binding in several studies (Martin et al., 2001; Raghavan et al., 1995), other analyses have indicated that it does not (Kim et al., 1999; Medesan et al., 1997; Oganessian et al., 2014).

The histidine residues on IgG confer the pH dependence of FcRn-IgG complex formation which is central to the functional activity of this receptor (Kim et al., 1994; Raghavan et al., 1995). Specifically, most naturally occurring IgGs bind with relatively high affinity to FcRn at pH 5.5-6.0, with the interaction becoming progressively weaker as near neutral pH is approached (Popov et al., 1996; Raghavan et al., 1995; Rodewald, 1976; Simister and Rees, 1985; Wallace and Rees, 1980; West and Bjorkman, 2000; Zhou et al., 2005). Consequently, the binding of most IgG isotypes with FcRn at physiological pH (7.3-7.4) is either negligible or of too low affinity to determine an accurate equilibrium dissociation constant. The IgG histidines interact with acidic residues on FcRn such as Glu117 in rodent FcRn or human FcRn [note that human FcRn is two residues shorter than rodent FcRn (Ahouse et al., 1993; Simister and Mostov, 1989; Story et al., 1994). The numbering system used for human FcRn in this review is based on homology alignment]. The X-ray crystallographic structures of rat

FcRn-rat IgG2a (Fc) and uncomplexed human FcRn were reported many years ago (Burmeister et al., 1994; Martin et al., 2001; West and Bjorkman, 2000), whereas a co-crystal structure of human FcRn with human IgG1 (Fc) was only recently described (Oganesyan et al., 2014). This latter study presented the tripartite complex of human FcRn with human serum albumin and an engineered human IgG1-derived Fc fragment with increased affinity for FcRn ['YTE' (Dall'Acqua et al., 2002; Dall'Acqua et al., 2006b), discussed further below]. Importantly, the structure demonstrates that through interactions with Glu117 on human FcRn, His310 on IgG is the major player in mediating the pH-dependence of the interaction. This analysis also confirmed earlier biophysical studies indicating that the albumin and IgG recognition sites on FcRn do not overlap (Andersen et al., 2006; Sand et al., 2014).

3. Cross-species differences in FcRn binding

Variations in residues encompassing the FcRn-IgG interaction site across species lead to differences in binding behavior that bear direct relevance to the use of mice as a preclinical model (Martin et al., 2001; Ober et al., 2001; Oganesyan et al., 2014). To date, affinities of FcRn for multimeric immune complexes (ICs) have not been reported due to the complexity of analyzing the binding of heterogeneous ICs to this receptor, resulting in the availability of data only for 'monomeric' IgGs (i.e. an IgG homodimer). Specifically, mouse FcRn has substantially higher affinities than human FcRn for binding to IgGs (Ober et al., 2001). For example, human FcRn binds very weakly, if at all, to most mouse IgG isotypes. In addition, the interaction of human IgG1 with human FcRn is about 15-fold lower in affinity compared with binding to mouse FcRn (370 nM vs. 24 nM at pH 6.0) (Zhou et al., 2005). This can impact the interpretation of preclinical data obtained using engineered (human) antibodies in mice (Dall'Acqua et al., 2002; Dall'Acqua et al., 2006b; Vaccaro et al., 2006). These cross-species differences have motivated the development of human FcRn transgenic mice that provide valuable models for the analyses of therapeutic antibodies (Haraya et al., 2014; Petkova et al., 2006; Proetzel and Roopenian, 2014; Zalevsky et al., 2010).

The molecular basis for the variations in binding characteristics between mouse and human FcRn has been elucidated by systematic replacement of human FcRn residues with the corresponding amino acids from mouse FcRn (Zhou et al., 2003; Zhou et al., 2005). This has resulted in the identification of two specific regions of FcRn that confer the distinct binding behavior: first, residues 132-147, including the non-conserved residue 137 [Glu in mouse FcRn; Leu in human FcRn (Ahouse et al., 1993; Story et al., 1994)]; second, residues 79-89, which in human FcRn is two amino acids shorter than in mouse FcRn (Ahouse et al., 1993; Story et al., 1994). Residue 137 of FcRn plays a dominant role in the cross-species difference (Zhou et al., 2003). Although this residue is Asp or Glu in rats, mice and dogs (Ahouse et al., 1993; Kacskovics et al., 2006; Simister and Mostov, 1989) and Leu in humans or possums (Adamski et al., 2000; Story et al., 1994), multiple other species such as camels, cows, pigs and sheep contain Arg at this position (Kacskovics et al., 2006; Kacskovics et al., 2000; Mayer et al., 2002; Schnulle and Hurley, 2003). Given the crucial role of residue 137 for the complexes characterized to date (Martin and Bjorkman, 1999; Oganesyan et al., 2014; Vaughn et al., 1997), it is therefore probable that the molecular

nature of IgG interactions with Arg137-containing FcRn molecules will be distinct to those for rodent, canine, possum or human FcRn.

4. The sites of FcRn expression

The expression of FcRn was originally believed to be restricted to sites involved in the delivery of maternal IgG during gestation (humans, rodents) and from mothers milk during the neonatal period (rodents) (Rodewald and Abrahamson, 1982; Rodewald and Kraehenbuhl, 1984; Simister and Rees, 1985; Wallace and Rees, 1980). Indeed, the initial identification of this receptor in the neonatal rodent gut led to its designation as the neonatal Fc receptor, or FcRn. However, the expression of this receptor in multiple tissues and cell types throughout life is now well defined (Rath et al., 2013; Roopenian and Akilesh, 2007; Ward and Ober, 2009). In addition to the presence of FcRn in endothelial, epithelial and the majority of hematopoietic cells (Akilesh et al., 2007; Borvak et al., 1998; Dickinson et al., 1999; Mi et al., 2008; Qiao et al., 2008; Zhu et al., 2001), this receptor is expressed in specialized cell types such as podocytes, the blood brain barrier and ocular tissues including the cornea, retina and conjunctiva (Akilesh et al., 2008; Schlachetzki et al., 2002; Zhang and Pardridge, 2001).

The ubiquitous expression of FcRn throughout the body has prompted studies directed towards defining the functional sites at which FcRn maintains IgG levels (Akilesh et al., 2007; Perez-Montoyo et al., 2009; Qiao et al., 2008). The use of adoptive transfers of hematopoietic cells from FcRn-deficient mice into wild type mice (and vice versa) indicate that these cells contribute to the regulation of IgG homeostasis (Akilesh et al., 2007; Qiao et al., 2008). Mice harboring a floxed FcRn allele that enables site-specific deletion following appropriate intercrossing with Cre-expressing strains have also been generated (Perez-Montoyo et al., 2009). The production of a mouse strain lacking FcRn expression in both hematopoietic and endothelial cells has resulted in the demonstration that, collectively, these cells are the primary sites at which IgG levels are regulated in vivo (Perez-Montoyo et al., 2009).

Beyond a role in IgG homeostasis, multiple studies have demonstrated that FcRn is a multitasking receptor with diverse functional roles related to its ability to transport antibodies within and across cells (Rath et al., 2013; Roopenian and Akilesh, 2007; Ward and Ober, 2009). In particular, the transport function of FcRn in epithelial cells has been extensively analyzed (Bitonti et al., 2004; Claypool et al., 2004; Dickinson et al., 1999; Firan et al., 2001; Ladinsky et al., 2012; McCarthy et al., 2000; Mi et al., 2008; Spiekermann et al., 2002). FcRn can also deliver IgGs across mucosal surfaces to confer protective immunity (Ko et al., 2014; Li et al., 2011; Yoshida et al., 2006a; Yoshida et al., 2006b). Further, FcRn expression in antigen presenting cells contributes to phagocytosis and antigen presentation, including cross-presentation, resulting in enhancement of both CD4+ and CD8+ T cell responses (Baker et al., 2011; Baker et al., 2013; Cervenak et al., 2011; Qiao et al., 2008; Vidarsson et al., 2006). The activity in cross-presentation enhances CD8+ T cell responses against tumors (Baker et al., 2013). These functions for FcRn have been reviewed elsewhere and will not be discussed further here (Baker et al., 2014; Roopenian and Akilesh, 2007; Ward and Ober, 2009).

5. Subcellular trafficking behavior of FcRn and IgG ligand

5.1. Trafficking analyses in endothelial cells

The intracellular trafficking pathways taken by FcRn and its IgG ligand have been investigated in transfected human microvasculature-derived endothelial cells (HMEC-1 cells) using fluorescence microscopy (Gan et al., 2009; Ober et al., 2004a; Ober et al., 2004b; Prabhat et al., 2007; Ram et al., 2008; Weflen et al., 2013). The interaction of the majority of IgG isotypes characterized to date with FcRn at the surface of most cell types is not permissive due to the near neutral pH of the extracellular environment. Thus, the consensus view is that IgG enters cells by fluid phase pinocytosis or any other cellular processes that engulf medium from the extracellular milieu. However, due to the technical limitations of imaging in the presence of high levels of (fluorescently labeled) IgG, this initial step of the pathway has not been amenable to microscopy analyses. The elucidation of subsequent steps using microscopy indicate that IgG is bound to FcRn in early (sorting) endosomes and subsequently sorted into tubulovesicular transport carriers (TCs) (Ober et al., 2004b). These TCs have also been observed using electron tomography of rat jejunal sections isolated from rats following intubation with nanogold labeled Fc fragments (He et al., 2008; Ladinsky et al., 2012). By contrast with salvaged IgG, antibody molecules that do not bind to FcRn due to low affinity or saturation of FcRn interaction sites fail to segregate into TCs and enter the degradative, lysosomal pathway (Ober et al., 2004b).

Recent studies using a combination of localized photoactivation and multifocal plane microscopy, involving the simultaneous imaging of several different focal planes in live cells (Prabhat et al., 2007; Prabhat et al., 2004), have been used to investigate the subcellular trafficking pathways taken by FcRn within endothelial cells (Gan et al., 2013). These analyses have shown that following segregation from sorting (early) endosomes, FcRn-positive TCs can take several different pathways (Fig. 1): first, TCs can traffick to the plasma membrane and undergo exocytosis (exocytic pathway). Second, they can be transferred to another sorting endosome (interendosomal transfer). Third, TCs can leave a sorting endosome and return to the same endosome in what appears to be a futile process (looping). Despite these different intracellular pathways, quantitative recycling assays reveal that the majority of IgG is recycled from the cells (Vaccaro et al., 2006; Ward et al., 2003). This is consistent with earlier analyses demonstrating that TCs can follow direct or indirect routes inside cells prior to being exocytosed (Prabhat et al., 2007). During exocytic release of IgG, FcRn-positive TCs fuse with the plasma membrane to release their cargo (Ober et al., 2004a; Prabhat et al., 2007). However, the low steady state level of FcRn on the plasma membrane indicates that this receptor is rapidly re-internalized following exocytosis.

It is well documented that multivalent ICs enter lysosomes following uptake into hematopoietic cells that are involved in antigen presentation and express both FcRn and the 'classical' FcγRs (Delamarre et al., 2005; Qiao et al., 2008; Trombetta and Mellman, 2005). However, until recently the fate of such ICs in FcRn-expressing cells that do not normally express FcγRs was unexplored. By contrast with monomeric IgGs, microscopy studies in HMEC-1 cells have revealed that multivalent ICs are excluded from tubular TCs as these compartments segregate from sorting endosomes, resulting in lysosomal delivery of both

FcRn and its bound cargo (Wefflen et al., 2013). Interestingly, deletion or replacement of the cytosolic tail of FcRn does not inhibit this lysosomal delivery pathway, suggesting that the physical nature of the complex is the primary driving force for exclusion from recycling TCs.

Although the principles of FcRn-mediated sorting of IgGs away from lysosomal degradation in endosomal compartments are likely to be similar across distinct cell types, the homeostatic role of hematopoietic cells (Akilesh et al., 2007; Perez-Montoyo et al., 2009; Qiao et al., 2008) indicates that it will also be instructive to analyze trafficking processes in these cells. For example, FcRn expression levels differ across cell types (Akilesh et al., 2007; Perez-Montoyo et al., 2009; Zhu et al., 2001). In addition, the endolysosomal and recycling pathways are expected to vary between endothelial and hematopoietic cells, given their distinct activities in antigen presentation and other cellular functions.

5.2. Transcytosis across epithelial barriers

FcRn can also transport antibodies bidirectionally across polarized cellular barriers such as epithelial cells, and the subcellular trafficking pathways have been extensively studied in intestinal epithelial cells and FcRn-transfected Madin-Darby canine kidney (MDCK) cells (Claypool et al., 2004; Claypool et al., 2002; Dickinson et al., 1999; Kuo et al., 2009; Ladinsky et al., 2012; Mi et al., 2008; Tzaban et al., 2009). This transport function is essential for FcRn-mediated delivery of antibodies to multiple sites in the body, including the mucosal surfaces for protective immunity (Ko et al., 2014; Li et al., 2011; Yoshida et al., 2006a; Yoshida et al., 2006b). On the other hand, FcRn-mediated transcytosis of IgG-opsinized human immunodeficiency virus type I has been reported to facilitate viral transmission by enhancing the delivery of this virus across epithelial barriers (Gupta et al., 2014).

FcRn-mediated transport can be exploited for the delivery of exogenous (therapeutic) antibodies or other biologics. For example, Fc-erythropoietin (Epo) fusion constructs are transported from the lungs into the bloodstream following inhalation (Bitonti et al., 2004; Spiekermann et al., 2002). More recently, Fc-coated, insulin-loaded nanoparticles have been shown to be transferred across the gut following oral delivery (Pridgen et al., 2013). A potential limitation of this approach is that the nanoparticles may accumulate and follow the lysosomal trafficking pathway in nontarget cell populations (Pridgen et al., 2013). Nevertheless, this strategy has considerable promise for the delivery of relatively high effective doses of biologic through the oral route.

6. Engineering FcRn-IgG interactions to modulate *in vivo* pharmacokinetics and transport

6.1. Half-life extension

Over the past decade or so, the use of Fc engineering to generate antibodies with increased *in vivo* half-lives and transport across cellular barriers has developed into a major area of interest for the production of 'second' generation therapeutic antibodies (Dall'Acqua et al.,

2006a; Hinton et al., 2004; Hinton et al., 2006; Vaccaro et al., 2006; Yeung et al., 2009; Zalevsky et al., 2010). In 1997, it was reported that the mutagenesis of residues surrounding the FcRn-IgG interaction site followed by phage display and selection could be used to isolate a mouse IgG1-derived Fc fragment with ~3.5 fold increased binding affinity for mouse FcRn at pH 6.0 and up to ~1.6-fold increased persistence in mice (Ghetie et al., 1997) (Table I). This was followed by a study in 2002 in which similar approaches resulted in the generation of human IgG1-derived Fc fragments with higher affinity for mouse and human FcRn (Dall'Acqua et al., 2002). Significantly, the selection for maintenance of pH-dependent binding (high affinity at around pH 6-6.5, very low affinity at pH 7.2-7.4) was not as stringent as for the earlier study, resulting in the isolation of mutated Fc fragments with significant binding to mouse FcRn at near neutral pH (Dall'Acqua et al., 2002). This loss of pH dependence resulted in shorter in vivo half lives in mice, despite higher affinity binding to FcRn at acidic pH. This study therefore provided a clear demonstration of the need for efficient release of ligand from FcRn following recycling and exocytosis at the plasma membrane. Nevertheless, due to the cross-species differences in FcRn-binding specificities (Ober et al., 2001), one of the mutants (Met252 to Tyr, Ser254 to Thr, Thr256 to Glu, or 'YTE') isolated in this study (Dall'Acqua et al., 2002) showed negligible binding to human FcRn at near neutral pH combined with enhanced affinity for this receptor at acidic, endosomal pH (~6.0). Consistent with these binding properties, the YTE mutant has an extended half-life in cynomolgus monkeys (almost 4-fold; 21.2 vs. 5.7 days) and humans (~3.7 fold; 69.5 vs. 18.9 days for 0.3 mg/Kg dose) and forms the basis of the YTE platform that is currently in clinical trials for several different indications (Dall'Acqua et al., 2006b; Robbie et al., 2013) (Table I).

Additional half-life extending mutations for human IgGs have been described that result in 1.5-5-fold increases in persistence over the wild type parent in non-human primates or human FcRn transgenic mice (Borrok et al., 2014; Datta-Mannan et al., 2012a; Hinton et al., 2004; Hinton et al., 2006; Monnet et al., 2014; Petkova et al., 2006; Wilson and Taura, 2013; Yeung et al., 2009; Zalevsky et al., 2010) (Table I). These mutations confer increased binding to FcRn at pH 6.0 with retention of low affinity interactions at near neutral pH. A recent structural study of the YTE mutant (Fc fragment) in complex with human FcRn revealed the molecular basis for the increased affinity, and has also been used to rationalize the affinity improvement for several other FcRn-enhanced antibodies (Borrok et al., 2014; Oganessian et al., 2014) (Fig. 2). Significantly, in preclinical studies in human FcRn transgenic mice, the M428L/N434S ('LS') mutations confer increased efficacy in tumor models (Zalevsky et al., 2010). Thus, engineering antibodies for half-life extension offers considerable promise to enable reduced, lower frequency dosing. Half-life extending mutations are also expected to increase FcRn-mediated transport across cellular barriers, and evidence to support this has been obtained using an ex vivo placental explant model (Vaccaro et al., 2006). In addition, a recent study has demonstrated that an anti-human immunodeficiency virus antibody with increased mucosal delivery through enhanced FcRn binding provides increased protection against viral infection in non-human primates (Ko et al., 2014).

The question arises as to what is the maximum achievable increase in persistence (and transport) using Fc engineering, particularly since retention of low affinity at near neutral

pH is essential for antibody recycling and exocytic release from FcRn-expressing cells? Several studies have demonstrated that, in general, affinity improvements for FcRn-IgG interactions at pH 6.0 are accompanied by increases in affinity at near neutral pH (Borrok et al., 2014; Dall'Acqua et al., 2002; Yeung et al., 2009). For example, Lowman and colleagues determined the affinities of a panel of engineered human IgG1 mutants for binding to human FcRn and showed that they are around 100-fold lower at near neutral pH than at pH 6.0 (Yeung et al., 2009). Comparison of the half-lives of two human IgG1 mutants with analogous affinities ($K_D \sim 1$ nM) for mouse FcRn at pH 6.0, but 10-fold differences (K_D s of 7.2 and 82 nM) at near neutral pH, has demonstrated the negative effect of increased binding at this higher pH on in vivo persistence (Ward and Ober, 2009). In this context, a recent study defined the threshold affinity for human FcRn at pH 7.4 that mitigates the half-life extending effect of affinity increases at pH 6.0 (Borrok et al., 2014). Based on pharmacokinetic studies in human FcRn transgenic mice, this threshold is between ~400 and ~900 nM. Given the counterbalancing effects of increased binding at pH 6.0 and pH 7.3-7.4 on in vivo persistence, the concomitant increase in binding strength at pH 6.0 and pH 7.4 therefore imposes a limit on the half-life extensions that can be achieved.

6.2. Naturally occurring antibodies with reduced pH dependent binding to FcRn

Although His435 is present in the majority of mouse and human IgG isotypes, this residue is replaced by Arg in a subset of human IgG3 allotypes (e.g. g3m16) and Tyr in mouse IgG2b (Kabat et al., 1991). The important contribution of His435 to FcRn interactions raises the question as to how these substitutions might affect binding. Studies in which His435 in human IgG1 was mutated to Arg, and reciprocally, Arg435 in human IgG3 mutated to His, demonstrate that the His-containing antibodies have higher affinities for FcRn at pH 6.0, longer in vivo half-lives and improved transport across the placental barrier (Einarsdottir et al., 2014; Kim et al., 1999; Stapleton et al., 2011). Consistent with the pKa of the Arg side chain, Arg-containing allotypes of IgG3 retain significant binding to FcRn at near neutral pH, which also contributes to the lower activity in functions dependent on FcRn-mediated transport. Similarly, relative to mouse IgG1 or IgG2a, mouse IgG2b binds with increased affinity to mouse or rat FcRn at pH ~7 (Raghavan et al., 1995; Zhou et al., 2003). These three mouse isotypes have a similar affinity for mouse FcRn at pH 6.0, whereas the reduced pH dependence of IgG2b contributes to shorter in vivo persistence (Pollock et al., 1990; Vieira and Rajewsky, 1988).

6.3. Does FcRn play a role in controlling bioavailability?

Although the majority of therapeutic antibodies are delivered intravenously, several are delivered via the subcutaneous route (Wang et al., 2008). Subcutaneous delivery offers the major advantage that antibodies can be self-administered, prompting interest in understanding the processes through which subcutaneously delivered therapeutics, including antibodies, enter the circulation. As a corollary, knowledge of these processes may inform antibody engineering strategies to increase the effective therapeutic dose.

Subcutaneous bioavailability of a therapeutic is defined as the amount of delivered dose entering the circulation. This is determined by the extent of catabolism at the injection site and the efficiency of systemic absorption via the lymphatics and across the blood vessels

(Wang et al., 2008). In FcRn-deficient mice, the subcutaneous bioavailability of a mouse IgG1 antibody was reported to be several-fold lower than that in wild type mice, implicating a role for FcRn in either local protection against catabolism, transcytotic delivery across cellular barriers or both (Wang et al., 2008). However, more recent studies directed towards determining whether affinity enhancement of an IgG for FcRn increases its subcutaneous bioavailability have generated discrepant results (Datta-Mannan et al., 2012b; Deng et al., 2012). In one report, a mutated mouse IgG2a (N434H) with 13-fold increased affinity for mouse FcRn at pH 6.0 and retention of almost negligible binding at pH 7.4 had improved bioavailability relative to its wild type counterpart in mice (Deng et al., 2012). By contrast, analyses in cynomolgus monkeys did not demonstrate increased bioavailability for IgG4 molecules containing the half-life extending mutations, T250Q/M428L (Datta-Mannan et al., 2012b). Given the importance of optimizing IgG delivery through parenteral routes, additional work needs to be carried out to define a possible role for FcRn.

6.4. Do the characteristics of FcRn-IgG interactions correlate with in vivo behavior?

It is established that loss of binding of an antibody for FcRn at acidic, endosomal pH results in decreased in vivo persistence and inefficient transport across cellular barriers (Kim et al., 1999; Medesan et al., 1997; Spiekermann et al., 2002). However, for engineered antibodies that retain, or have increased affinity at this pH, there are discrepancies concerning whether the biophysical nature of an FcRn-IgG interaction correlates with its in vivo half-life/pharmacokinetic properties (Dall'Acqua et al., 2002; Datta-Mannan et al., 2007; Deng et al., 2010; Hinton et al., 2006; Suzuki et al., 2010; Yeung et al., 2009). Inconsistencies between binding properties and in vivo clearance may in part be due to variations in the binding assays used (e.g. immobilized FcRn vs. IgG) and the different experimental approaches and models employed to determine interaction affinities/kinetics by surface plasmon resonance (Datta-Mannan et al., 2007; Datta-Mannan and Wroblewski, 2014; Gurbaxani et al., 2006; Neuber et al., 2014; Wang et al., 2011a; West and Bjorkman, 2000; Yeung et al., 2009; Zhou et al., 2005). Multiple studies also demonstrate the negative effect of FcRn binding at near neutral pH on in vivo persistence (Borrok et al., 2014; Dall'Acqua et al., 2002; Datta-Mannan et al., 2007; Vaccaro et al., 2006; Yeung et al., 2009), and variations in assays to assess this may lead to apparently conflicting data. However, even if there is concordance concerning interaction behavior, this does not uniformly correlate with in vivo pharmacokinetics (Datta-Mannan and Wroblewski, 2014). There are several additional factors that may contribute to this lack of correlation: first, for antibodies that bind negligibly to FcRn at near neutral pH, uptake into the majority of cells is dependent on fluid phase pinocytosis. Significantly, studies of Igawa and colleagues in mice and cynomolgus monkeys (Igawa et al., 2010b) have indicated that this can be affected by the isoelectric point (pI) of the antibody since the surface of cells is negatively charged. Hence the higher the pI, the greater the internalization of antibody into cells and possibility of lysosomal degradation. Specifically, the substitution of both complementarity determining region (CDR) and framework residues with acidic amino acids in an anti-interleukin 6 receptor (IL-6R) antibody lowered the pI, resulting in increased in vivo persistence (Igawa et al., 2010b). Further, the choice of (light chain) framework for a humanized anti-hepatitis C glycoprotein antibody modulates the pI, conferring distinct pharmacokinetic properties in rats (Li et al., 2014). Second, for some antibodies, the endosomal environment (salt

concentration, temperature etc.) may result in different binding properties to those observed when carrying out interaction analyses in vitro, typically at 25°C. Third, the degradation or modification of antibodies during storage can lead to loss of binding affinity for FcRn. For example, methionine oxidation of two residues, Met252 and Met428, in proximity to the FcRn-(human) IgG1 interaction site can lead to decreased in vivo half-life (Bertolotti-Ciarlet et al., 2009; Gao et al., 2014; Wang et al., 2011b). Fourth, when targeting membrane-bound receptors, or multivalent soluble ligands, receptor-antibody internalization and degradation or IC-mediated internalization by FcγRs, respectively, may contribute to clearance (McKeage and Perry, 2002; Rowinsky et al., 2004; Suzuki et al., 2010; Tabrizi et al., 2006). Studies demonstrating that FcRn can contribute to IC trafficking into lysosomes following FcγR-mediated internalization into endosomes (Baker et al., 2011; Qiao et al., 2008), indicate that this latter pathway of enhanced clearance also has some FcRn dependency. The effects of ‘antigen sinks’, whether soluble or membrane bound, can become particularly relevant when high levels of antigen are being targeted.

Given the possible sources of inconsistencies between FcRn binding characteristics and in vivo properties, the question arises as to how can in vitro properties be reliably translated to in vivo behavior? One possibility that may overcome the first three limitations described above is to use in vitro subcellular trafficking analyses in FcRn-expressing cells as an additional correlate for in vivo behavior. Given the variability in binding constants from one laboratory to the next, it may be also be instructive to develop a standardized protocol for FcRn-IgG interaction studies as discussed in (Datta-Mannan and Wroblewski, 2014; Neuber et al., 2014; Yeung et al., 2009). This becomes particularly important in light of the Food and Drug Administration’s requirement to report FcRn interaction properties for antibodies of potential therapeutic value.

In the context of the molecular nature of FcRn-IgG interactions, the Fab arms of antibody have been reported to affect binding to FcRn (Wang et al., 2011a) although this is discordant with the observations of others (Neuber et al., 2014). Interestingly, the recent use of hydrogen/deuterium exchange mass spectrometry to analyze human FcRn/human IgG1 complexes provides support for the involvement of Fab residues in binding to FcRn or a conformational link between the Fc and Fab fragments following complex formation (Jensen et al., 2015). Similarly, the protein moiety on Fc-fusions or the interaction of soluble ligand (TNF-α) with cognate antibody can modulate FcRn binding (Suzuki et al., 2010). Consequently, in addition to the possible enhancement of clearance by antigen sinks discussed above, the concentration of soluble ligand levels can affect pharmacokinetic behavior through altering FcRn interactions.

7. Modulating IgG dynamics by FcRn inhibition

By contrast with half-life extension of a therapeutic antibody, the inhibition of FcRn reduces antibody levels in the body. Several classes of FcRn inhibitors have been developed: peptides or small molecules (Low and Mezo, 2009; Mezo et al., 2008; Wang et al., 2013), anti-FcRn antibodies that bind through their V-regions (Getman and Balthasar, 2005) and Fc-engineered antibodies called Abdegs [for ‘antibodies that enhance IgG degradation’ (Vaccaro et al., 2005); Fig. 3]. All of these inhibitors recognize FcRn with increased affinity

in the pH range 6.0-7.4 and competitively block IgG binding. Consequently, they are efficiently internalized into FcRn-expressing cells through FcRn-mediated endocytosis, compete with wild type IgGs for FcRn binding in endosomes and are not released during exocytic events at the cell surface (Vaccaro et al., 2005). The inhibitors have been demonstrated to reduce endogenous IgG levels in mice, and their efficacy in clearing pathogenic, autoreactive antibodies and ameliorating disease in mouse models of idiopathic thrombocytopenic purpura (ITP), myasthenia gravis, arthritis and multiple sclerosis has been demonstrated (Challa et al., 2013; Getman and Balthasar, 2005; Liu et al., 2007; Patel et al., 2011).

A potential drawback of the use of FcRn inhibitors is that they exhibit relatively short in vivo half-lives due to their increased binding to FcRn at near neutral pH (Dall'Acqua et al., 2002; Getman and Balthasar, 2005; Vaccaro et al., 2006). Inhibitors based on Fc-engineering have been shown to follow the constitutive degradation pathway for FcRn and traffick into lysosomes (Gan et al., 2009). Thus, for the treatment of chronic diseases frequent dosing may be necessary, although such agents could have utility in ameliorating disease flares. In this context, half-life extended antibodies which retain very low affinity binding to FcRn at near neutral pH also have a competitive advantage over their wild type counterparts (Petkova et al., 2006). However, for effective competition with FcRn there is a need to use higher doses of antibodies of this class compared with shorter-lived inhibitors that accumulate more efficiently in cells through FcRn-mediated binding at the cell surface (Petkova et al., 2006).

There are multiple examples of situations where it may be desirable to induce a rapid, one-time clearance of antibodies in vivo, including the elimination of radiolabeled, circulating antibody during tumor imaging and of antibody:toxin complexes. Due to their high specificity, antibodies represent attractive agents for use in diagnostic imaging. However, their prolonged in vivo persistence results in high levels of background and can also induce off-target tissue damage (Goldstein et al., 2013; Jaggi et al., 2007; Wu, 2014). The delivery of an Fc-engineered inhibitor (Abdeg) following the loading of tumor with radiolabeled antibody results in significant improvements in contrast during positron emission tomography [PET (Swiercz et al., 2014)]. As such, Abdegs or other FcRn inhibitors have promise for use in PET and other whole body imaging modalities involving diagnostic antibodies. Similarly, FcRn blockade could have applications in reducing dose limiting toxicities following the loading of tumor with radiolabeled antibodies during radioimmunotherapy (Goldenberg et al., 2012; Palanca-Wessels and Press, 2010).

8. Targeting antibody variable regions to alter antigen dynamics

8.1. Generation of recycling antibodies

The advantages of half-life extension with respect to the dosing of a therapeutic antibody are clear. However, if an antibody is being used to target a soluble ligand, such as a cytokine or other inflammatory mediator, the antibody itself can prolong the in vivo persistence of its antigen by 'buffering' (Davda and Hansen, 2010; Finkelman et al., 1993; Junghans and Anderson, 1996; O'Hear and Foote, 2005; Phelan et al., 2008; Rehlaender and Cho, 1998). This effect can result in substantial increases in antigen concentration. Further, a related

problem occurs if the concentration of antigen is high since stoichiometric amounts of antibody are required. For example, complement C5 is typically present at high levels in the patient population indicated for treatment, necessitating the use of very large doses of the anti-C5 antibody, eculizumab (Zareba, 2007).

Strategies to overcome the limitations related to antibody buffering and the need to use stoichiometric antibody doses have recently been explored in several different studies (Chaparro-Riggers et al., 2012; Devanaboyina et al., 2013; Igawa et al., 2010a; Igawa et al., 2014). The rationale used in these analyses is to engineer the V regions of antibodies to endow them with relatively tight binding to antigen at near neutral pH and release at endosomal, acidic pH. Antibodies with these interaction properties are expected to release antigen in acidic endosomal compartments following internalization of antibody-antigen complexes into cells (Fig. 4). Consequently, antigen enters the lysosomal pathway whereas the antibody is recycled for re-use. The use of these 'recycling' antibodies (Igawa et al., 2014) not only results in reductions in the buffering effect, but also enables lower doses of antibody to be effective.

Antibodies with substantially higher affinity at near neutral pH than at pH 5.5-6.0 are rarely isolated from immunized animals (Igawa et al., 2014). The use of antibody engineering approaches is therefore necessary to generate effective recycling or 'acid-switched' antibodies. It is well known that the pKa of histidine is appropriate for introducing pH dependence in the physiological pH range into protein-protein interactions. Typically, the engineering of pH-dependent antigen binding has involved the use of histidine scanning, whereby the residues in the CDRs of the antibody are systematically replaced with histidines (Chaparro-Riggers et al., 2012; Devanaboyina et al., 2013; Igawa et al., 2010a). As an alternative approach, CDR residues of a single domain VHH antibody have been mutated to histidine or retained as wild type amino acids to generate a combinatorial histidine library, followed by the use of phage display (Murtaugh et al., 2011). Computational design can also be implemented to generate pH-dependent protein-protein interactions (Sarkar et al., 2002; Strauch et al., 2014).

The efficacy of acid-switching in inducing increased antigen clearance rates in mouse and/or cynomolgus monkey models has been demonstrated for antibodies specific for the cytokine IL-6 and soluble IL-6R (Devanaboyina et al., 2013; Igawa et al., 2010a). In addition, the regulator of plasma levels of low density lipoprotein (LDL), proprotein convertase subtilisin kexin type 9 (PCSK9), has been targeted (Chaparro-Riggers et al., 2012). PCSK9 binds to the LDL receptor (LDLR) and redirects the receptor from the recycling pathway into lysosomes. This results in lower LDLR levels with consequent increases in plasma LDL. pH-independent antibodies specific for PCSK9 are rapidly consumed via the lysosomal pathway following delivery, whereas their in vivo persistence and efficacy can be increased by conversion to pH-dependent variants.

The advantages of pH-dependent antigen binding can also be exploited for antibodies specific for membrane bound receptors (Igawa et al., 2010a). Antibody binding to membrane-associated target across the pH range 6-7.4 usually results in biphasic clearance kinetics due to receptor-mediated internalization and trafficking into lysosomes (target-

mediated clearance) followed by a slower elimination phase of antibody that is not receptor-bound (McKeage and Perry, 2002; Rowinsky et al., 2004; Tabrizi et al., 2006). This effect is exacerbated for receptors that are expressed at high levels. The introduction of pH-dependent binding into the antibody, with higher affinity at near neutral pH compared with acidic endosomal pH, can ameliorate target-mediated clearance by enabling the dissociation of antibody from internalized receptor in endosomes followed by FcRn-mediated recycling of the free antibody (Chaparro-Riggers et al., 2012; Igawa et al., 2010a). For example, a pH-dependent recycling antibody specific for IL-6R (which can exist in both soluble and membrane bound form) has superior properties with respect to both antibody persistence and the lowering of the inflammatory mediators associated with IL-6:IL-6R signaling compared with its pH-independent counterpart (Igawa et al., 2010a).

Fluorescence microscopy studies have given insight into the subcellular trafficking behavior of an engineered recycling antibody for antibody:IL-6 complexes (Devanaboyina et al., 2013). A highly pH-dependent variant of the parent antibody was generated by systematically replacing CDR3 residues of the heavy and light chain variable (VH and VL) domains with His, resulting in a mutant containing an Asp to His substitution in CDR3 of the heavy chain with the desired properties. In the presence of this antibody, IL-6 accumulates in the vacuole of sorting endosomes, ultimately trafficking into lysosomes, whereas the antibody associates with FcRn on the endosomal limiting membrane and is recycled in tubulovesicular TCs (Fig. 5) (Devanaboyina et al., 2013). By contrast, IL-6 molecules associated with antibodies that do not show pH-dependent antigen binding are recycled as tripartite FcRn:IgG:IL-6 complexes (Devanaboyina et al., 2013). Consistent with the subcellular trafficking behavior, IL-6 has a shorter in vivo persistence in the presence of the pH-dependent antibody compared with that observed for pH-independent antibody complexes.

A persistent challenge for the generation of recycling antibodies is to engineer or design mutations that result in very low affinity for antigen at pH 5.5-6.0 whilst retaining high affinity at physiological pH. The requisite affinity at near neutral pH will depend on the nature of the antigen. Further, although the off-rate of the antibody-antigen interaction at pH 6.0 has been suggested to be a more important factor than affinity in improving the pharmacokinetic profile of an anti-PCSK9 antibody (Chaparro-Riggers et al., 2012), the generality of this suggestion merits further investigation. Consequently, there remains a need at both the level of experimental and modeling studies to better understand the design principles for recycling antibodies of high efficacy. Further, it may be possible to exploit knowledge concerning differences between the endosomal and extracellular environment other than pH, such as Ca^{2+} concentrations, to generate antibodies that rapidly dissociate from their antigen within early endosomes (Igawa et al., 2014).

8.2. Sweeping antibodies

Receptor-mediated endocytosis of ligand followed by lysosomal degradation is a well-defined subcellular trafficking pathway. Compared with fluid phase uptake, receptor-mediated internalization is a highly efficient process for the accumulation of ligand within cells. This has prompted the design of engineered antibodies that, through binding to FcRn

with moderate affinity at near neutral pH, efficiently accumulate in cells with their associated antigen (Igawa et al., 2013; Igawa et al., 2014). These antibodies, combined with pH-dependent modulation of their variable region/antigen interaction, can be extremely effective in clearing soluble antigens. Antibodies of this class have appropriately been designated ‘sweeping’ antibodies and are substantially more potent than conventional antibodies in mediating antigen removal (Igawa et al., 2013; Igawa et al., 2014). As expected, there is a counterbalance between increased cellular uptake due to higher affinity at neutral pH and in vivo persistence. Nevertheless, appropriate tuning of the FcRn-binding properties of sweeping antibodies should be possible to enable optimization of the extent and duration of antigen clearance.

9. Future directions

Major progress has been made in engineering both the Fc regions and variable domains of antibodies for half-life extension and pH-dependent binding, with consequent improvements in efficacy in multiple systems. To facilitate further development, an improved understanding of the cell biology of different FcRn-expressing cells is desirable. For example, knowledge concerning fluid phase uptake processes, recycling rates, the endosomal environment and FcRn endocytic rates is limited. Further, variations in these characteristics across cell types, such as hematopoietic vs. endothelial cells, are unexplored. A more complete understanding of these properties could lead to the design of more effective therapeutics.

Acknowledgements

We are grateful to our current and former laboratory members and collaborators who have contributed to our FcRn-related studies. We thank Ramraj Velmurugan and Marietta Kovacs for expert assistance with manuscript preparation. The research of the authors described herein was supported by grants from the NIH (RO1 AI039167, RO1 AI055556, RO1 AR056478) CPRIT (RP110070, RP110441), National Multiple Sclerosis Society (RG 4308) and MedImmune (Scientific Research Agreement) to E.S.W. and from the NIH (RO1 GM071048 and RO1085575) and CPRIT (RP110441) to R.J.O.

Abbreviations

Abdeg	antibodies that enhance IgG degradation
CDR	complementarity determining region
Epo	erythropoietin
HMEC	human microvasculature-derived endothelial cells
ITP	idiopathic thrombocytopenic purpura
IC	immune complex
IL-6	interleukin-6
IL-6R	interleukin-6 receptor
LDL	low density lipoprotein
LDLR	low density lipoprotein receptor

MDCK	Madin-Darby canine kidney
PET	positron emission tomography
PCSK9	proprotein convertase subtilisin kexin type 9
pI	isoelectric point
TC	transport carrier
VH	variable heavy
VL	variable light

References

- Adamski FM, et al. Expression of the Fc receptor in the mammary gland during lactation in the marsupial *Trichosurus vulpecula* (brush-tail possum). *Mol. Immunol.* 2000; 37:435–444. [PubMed: 11090878]
- Ahouse JJ, et al. Mouse MHC class I-like Fc receptor encoded outside the MHC. *J. Immunol.* 1993; 151:6076–6088. [PubMed: 7504013]
- Akilesh S, et al. Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism. *J. Immunol.* 2007; 179:4580–4588. [PubMed: 17878355]
- Akilesh S, et al. Podocytes use FcRn to clear IgG from the glomerular basement membrane. *Proc. Natl. Acad. Sci. USA.* 2008; 105:967–972. [PubMed: 18198272]
- Andersen JT, et al. The conserved histidine 166 residue of the human neonatal Fc receptor heavy chain is critical for the pH-dependent binding to albumin. *Eur. J. Immunol.* 2006; 36:3044–3051. [PubMed: 17048273]
- Baker K, et al. Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8-CD11b+ dendritic cells. *Proc. Natl. Acad. Sci. USA.* 2011; 108:9927–9932. [PubMed: 21628593]
- Baker K, et al. Neonatal Fc receptor expression in dendritic cells mediates protective immunity against colorectal cancer. *Immunity.* 2013; 39:1095–1107. [PubMed: 24290911]
- Baker K, et al. The role of FcRn in antigen presentation. *Front. Immunol.* 2014; 5:408. [PubMed: 25221553]
- Bertolotti-Ciarlet A, et al. Impact of methionine oxidation on the binding of human IgG1 to FcRn and Fcγ receptors. *Mol. Immunol.* 2009; 46:1878–1882. [PubMed: 19269032]
- Bitonti AJ, et al. Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. *Proc. Natl. Acad. Sci. USA.* 2004; 101:9763–9768. [PubMed: 15210944]
- Borrok MJ, et al. pH-dependent binding engineering reveals an FcRn affinity threshold which governs IgG recycling. *J. Biol. Chem.* 2014
- Borvak J, et al. Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice. *Int. Immunol.* 1998; 10:1289–1298. [PubMed: 9786428]
- Burmeister WP, et al. Crystal structure of the complex of rat neonatal Fc receptor with Fc. *Nature.* 1994; 372:379–383. [PubMed: 7969498]
- Cervenak J, et al. Neonatal FcR overexpression boosts humoral immune response in transgenic mice. *J. Immunol.* 2011; 186:959–68. [PubMed: 21148035]
- Challa DK, et al. Autoantibody depletion ameliorates disease in murine experimental autoimmune encephalomyelitis. *MAbs.* 2013; 5:655–659. [PubMed: 23846320]
- Chaparro-Riggers J, et al. Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9. *J. Biol. Chem.* 2012; 287:11090–11097. [PubMed: 22294692]

- Chaudhury C, et al. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. *J. Exp. Med.* 2003; 197:315–322. [PubMed: 12566415]
- Claypool SM, et al. Bidirectional transepithelial IgG transport by a strongly polarized basolateral membrane Fc- γ receptor. *Mol. Biol. Cell.* 2004; 15:1746–1759. [PubMed: 14767057]
- Claypool SM, et al. Functional reconstitution of human FcRn in Madin-Darby canine kidney cells requires co-expressed human β 2-microglobulin. *J. Biol. Chem.* 2002; 277:28038–28050. [PubMed: 12023961]
- Dall'Acqua W, et al. Increasing the affinity of a human IgG1 to the neonatal Fc receptor: biological consequences. *J. Immunol.* 2002; 169:5171–5180. [PubMed: 12391234]
- Dall'Acqua WF, et al. Modulation of the effector functions of a human IgG1 through engineering of its hinge region. *J. Immunol.* 2006a; 177:1129–1138. [PubMed: 16818770]
- Dall'Acqua WF, et al. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). *J. Biol. Chem.* 2006b; 281:23514–23524. [PubMed: 16793771]
- Datta-Mannan A, et al. FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys. *Drug. Metab. Dispos.* 2012a; 40:1545–1555. [PubMed: 22584253]
- Datta-Mannan A, et al. Influence of improved FcRn binding on the subcutaneous bioavailability of monoclonal antibodies in cynomolgus monkeys. *MAbs.* 2012b; 4:267–273. [PubMed: 22377715]
- Datta-Mannan A, et al. Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates. *Drug Metab. Dispos.* 2007; 35:86–94. [PubMed: 17050651]
- Datta-Mannan A, Wroblewski VJ. Application of FcRn binding assays to guide mAb development. *Drug Metab. Dispos.* 2014; 42:1867–1872. [PubMed: 25024401]
- Davda JP, Hansen RJ. Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets. *MAbs.* 2010; 2:576–588. [PubMed: 20676036]
- Deisenhofer J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from *Staphylococcus aureus* at 2.9- and 2.8-Å resolution. *Biochemistry.* 1981; 20:2361–2370. [PubMed: 7236608]
- Delamarre L, et al. Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. *Science.* 2005; 307:1630–1634. [PubMed: 15761154]
- Deng R, et al. Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor- α antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. *Drug. Metab. Dispos.* 2010; 38:600–605. [PubMed: 20071453]
- Deng R, et al. Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mice. *MAbs.* 2012; 4:101–109. [PubMed: 22327433]
- Devanaboyina SC, et al. The effect of pH dependence of antibody-antigen interactions on subcellular trafficking dynamics. *MAbs.* 2013; 5:851–859. [PubMed: 24492341]
- Dickinson BL, et al. Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. *J. Clin. Invest.* 1999; 104:903–911. [PubMed: 10510331]
- Einarsdottir H, et al. H435-containing immunoglobulin G3 allotypes are transported efficiently across the human placenta: implications for alloantibody-mediated diseases of the newborn. *Transfusion.* 2014; 54:665–671. [PubMed: 23829325]
- Finkelman FD, et al. Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. *J. Immunol.* 1993; 151:1235–1244. [PubMed: 8393043]
- Firan M, et al. The MHC class I related receptor, FcRn, plays an essential role in the maternofetal transfer of gammaglobulin in humans. *Int. Immunol.* 2001; 13:993–1002. [PubMed: 11470769]
- Gan Z, et al. Using multifocal plane microscopy to reveal novel trafficking processes in the recycling pathway. *J. Cell. Sci.* 2013; 126:1176–1188. [PubMed: 23345403]
- Gan Z, et al. Analyses of the recycling receptor, FcRn, in live cells reveal novel pathways for lysosomal delivery. *Traffic.* 2009; 10:600–614. [PubMed: 19192244]

- Gao X, et al. Effect of individual Fc methionine oxidation on FcRn binding: Met252 oxidation impairs FcRn binding more profoundly than Met428 oxidation. *J. Pharm. Sci.* 2014
- Getman KE, Balthasar JP. Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions. *J. Pharm. Sci.* 2005; 94:718–729. [PubMed: 15682382]
- Ghetie V, et al. Abnormally short serum half-lives of IgG in β 2-microglobulin-deficient mice. *Eur. J. Immunol.* 1996; 26:690–696. [PubMed: 8605939]
- Ghetie V, et al. Increasing the serum persistence of an IgG fragment by random mutagenesis. *Nat. Biotechnol.* 1997; 15:637–640. [PubMed: 9219265]
- Goldenberg DM, et al. Pretargeted molecular imaging and radioimmunotherapy. *Theranostics.* 2012; 2:523–540. [PubMed: 22737190]
- Goldstein R, et al. Developments in single photon emission computed tomography and PET-based HER2 molecular imaging for breast cancer. *Expert Rev. Anticancer Ther.* 2013; 13:359–373. [PubMed: 23477521]
- Gupta S, et al. Enhanced in vitro transcytosis of simian immunodeficiency virus mediated by vaccine-induced antibody predicts transmitted/founder strain number after rectal challenge. *J. Infect. Dis.* 2014; 211:45–52. [PubMed: 24850790]
- Gurbaxani B, et al. Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life. *Mol. Immunol.* 2006; 43:1462–1473. [PubMed: 16139891]
- Haraya K, et al. Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody. *Xenobiotica.* 2014; 44:1127–1134. [PubMed: 25030041]
- He W, et al. FcRn-mediated antibody transport across epithelial cells revealed by electron tomography. *Nature.* 2008; 455:542–546. [PubMed: 18818657]
- Hinton PR, et al. Engineered human IgG antibodies with longer serum half-lives in primates. *J. Biol. Chem.* 2004; 279:6213–6216. [PubMed: 14699147]
- Hinton PR, et al. An engineered human IgG1 antibody with longer serum half-life. *J. Immunol.* 2006; 176:346–356. [PubMed: 16365427]
- Igawa T, et al. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. *Nat. Biotechnol.* 2010a; 28:1203–1207. [PubMed: 20953198]
- Igawa T, et al. Engineered monoclonal antibody with novel antigen-sweeping activity in vivo. *PLoS. One.* 2013; 8:e63236. [PubMed: 23667591]
- Igawa T, et al. pH-dependent antigen-binding antibodies as a novel therapeutic modality. *Biochim. Biophys. Acta.* 2014; 1844:1943–1950. [PubMed: 25125373]
- Igawa T, et al. Reduced elimination of IgG antibodies by engineering the variable region. *Protein Eng. Des. Sel.* 2010b; 23:385–392. [PubMed: 20159773]
- Israel EJ, et al. Increased clearance of IgG in mice that lack β 2-microglobulin: possible protective role of FcRn. *Immunology.* 1996; 89:573–578. [PubMed: 9014824]
- Jaggi JS, et al. Improved tumor imaging and therapy via i.v. IgG-mediated time-sequential modulation of neonatal Fc receptor. *J. Clin. Invest.* 2007; 117:2422–2430. [PubMed: 17717602]
- Jensen PF, et al. Investigating the interaction between the neonatal Fc receptor and monoclonal antibody variants by hydrogen/deuterium exchange mass spectrometry. *Mol. Cell. Proteomics.* 2015; 14:148–161. [PubMed: 25378534]
- Junghans RP, Anderson CL. The protection receptor for IgG catabolism is the β 2-microglobulin-containing neonatal intestinal transport receptor. *Proc. Natl. Acad. Sci. USA.* 1996; 93:5512–5516. [PubMed: 8643606]
- Kabat, EA., et al. Sequences of proteins of immunological interest. U.S. Dept. of Health and Human Services; 1991.
- Kacs Kovics I, et al. Cloning and characterization of the dromedary (*Camelus dromedarius*) neonatal Fc receptor (drFcRn). *Dev. Comp Immunol.* 2006; 30:1203–1215. [PubMed: 16690125]
- Kacs Kovics I, et al. Cloning and characterization of the bovine MHC class I-like Fc receptor. *J. Immunol.* 2000; 164:1889–1897. [PubMed: 10657638]

- Kim JK, et al. Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn. *Eur. J. Immunol.* 1999; 29:2819–2825. [PubMed: 10508256]
- Kim JK, et al. Identifying amino acid residues that influence plasma clearance of murine IgG1 fragments by site-directed mutagenesis. *Eur. J. Immunol.* 1994; 24:542–548. [PubMed: 8125126]
- Ko SY, et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. *Nature.* 2014; 514:642–645. [PubMed: 25119033]
- Kuo TT, et al. N-glycan moieties in neonatal Fc receptor determine steady-state membrane distribution and directional transport of IgG. *J. Biol. Chem.* 2009; 284:8292–8300. [PubMed: 19164298]
- Ladinsky MS, et al. Electron tomography of late stages of FcRn-mediated antibody transcytosis in neonatal rat small intestine. *Mol. Biol. Cell.* 2012; 23:2537–2545. [PubMed: 22573886]
- Li B, et al. Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge. *MAbs.* 2014; 6:1255–1264. [PubMed: 25517310]
- Li Z, et al. Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection. *Proc. Natl. Acad. Sci. USA.* 2011; 108:4388–4393. [PubMed: 21368166]
- Liu L, et al. Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade. *J. Immunol.* 2007; 178:5390–5398. [PubMed: 17404325]
- Low SC, Mezo AR. Inhibitors of the FcRn:IgG protein-protein interaction. *AAPS J.* 2009; 11:432–434. [PubMed: 19499344]
- Martin WL, Bjorkman PJ. Characterization of the 2:1 complex between the class I MHC-related Fc receptor and its Fc ligand in solution. *Biochemistry.* 1999; 38:12639–12647. [PubMed: 10504233]
- Martin WL, et al. Crystal structure at 2.8 Å of an FcRn/heterodimeric Fc complex: mechanism of pH dependent binding. *Mol. Cell.* 2001; 7:867–877. [PubMed: 11336709]
- Mayer B, et al. Redistribution of the sheep neonatal Fc receptor in the mammary gland around the time of parturition in ewes and its localization in the small intestine of neonatal lambs. *Immunology.* 2002; 107:288–296. [PubMed: 12423304]
- McCarthy KM, et al. Bidirectional transcytosis of IgG by the rat neonatal Fc receptor expressed in a rat kidney cell line: a system to study protein transport across epithelia. *J. Cell Sci.* 2000; 113:1277–1285. [PubMed: 10704378]
- McKeage K, Perry CM. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. *Drugs.* 2002; 62:209–243. [PubMed: 11790161]
- Medesan C, et al. Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1. *J. Immunol.* 1997; 158:2211–2217. [PubMed: 9036967]
- Mezo AR, et al. Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn. *Proc. Natl. Acad. Sci. USA.* 2008; 105:2337–2342. [PubMed: 18272495]
- Mi W, et al. Targeting the neonatal Fc receptor for antigen delivery using engineered Fc fragments. *J. Immunol.* 2008; 181:7550–7561. [PubMed: 19017944]
- Monnet C, et al. Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody. *MAbs.* 2014; 6:422–436. [PubMed: 24492301]
- Murtaugh ML, et al. A combinatorial histidine scanning library approach to engineer highly pH-dependent protein switches. *Protein Sci.* 2011; 20:1619–1631. [PubMed: 21766385]
- Neuber T, et al. Characterization and screening of IgG binding to the neonatal Fc receptor. *MAbs.* 2014; 6:928–942. [PubMed: 24802048]
- O'Hear CE, Foote J. Antibody buffering of a ligand in vivo. *Proc. Natl. Acad. Sci. USA.* 2005; 102:40–44. [PubMed: 15615858]
- Ober RJ, et al. Exocytosis of IgG as mediated by the receptor, FcRn: An analysis at the single-molecule level. *Proc. Natl. Acad. Sci. USA.* 2004a; 101:11076–11081. [PubMed: 15258288]
- Ober RJ, et al. Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn. *J. Immunol.* 2004b; 172:2021–2029. [PubMed: 14764666]
- Ober RJ, et al. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. *Int. Immunol.* 2001; 13:1551–1559. [PubMed: 11717196]
- Oganesyan V, et al. Structural insights into neonatal Fc receptor-based recycling mechanisms. *J. Biol. Chem.* 2014; 289:7812–7824. [PubMed: 24469444]

- Palanca-Wessels MC, Press OW. Improving the efficacy of radioimmunotherapy for non-Hodgkin lymphomas. *Cancer*. 2010; 116:1126–1133. [PubMed: 20127945]
- Patel DA, et al. Neonatal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine model. *J. Immunol*. 2011; 187:1015–22. [PubMed: 21690327]
- Perez-Montoyo H, et al. Conditional deletion of the MHC Class I-related receptor, FcRn, reveals the sites of IgG homeostasis in mice. *Proc. Natl. Acad. Sci. USA*. 2009; 106:2788–2793. [PubMed: 19188594]
- Petkova SB, et al. Human antibodies induce arthritis in mice deficient in the low-affinity inhibitory IgG receptor FcγRIIB. *J. Exp. Med*. 2006; 203:275–280. [PubMed: 16476768]
- Phelan JD, et al. Cutting edge: mechanism of enhancement of in vivo cytokine effects by anti-cytokine monoclonal antibodies. *J. Immunol*. 2008; 180:44–48. [PubMed: 18097002]
- Pollock RR, et al. Intravascular metabolism of normal and mutant mouse immunoglobulin molecules. *Eur. J. Immunol*. 1990; 20:2021–2027. [PubMed: 2120072]
- Popov S, et al. The stoichiometry and affinity of the interaction of murine Fc fragments with the MHC class I-related receptor, FcRn. *Mol. Immunol*. 1996; 33:521–530. [PubMed: 8700168]
- Prabhat P, et al. Elucidation of intracellular recycling pathways leading to exocytosis of the Fc receptor, FcRn, by using multifocal plane microscopy. *Proc. Natl. Acad. Sci. USA*. 2007; 104:5889–5894. [PubMed: 17384151]
- Prabhat P, et al. Simultaneous imaging of different focal planes in fluorescence microscopy for the study of cellular dynamics in three dimensions. *IEEE Trans. Nanobioscience*. 2004; 3:237–242. [PubMed: 15631134]
- Pridgen EM, et al. Transepithelial transport of Fc-targeted nanoparticles by the neonatal Fc receptor for oral delivery. *Sci. Transl. Med*. 2013; 5:213ra167.
- Proetzel G, Roopenian DC. Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies. *Methods*. 2014; 65:148–153. [PubMed: 23867339]
- Qiao SW, et al. Dependence of antibody-mediated presentation of antigen on FcRn. *Proc. Natl. Acad. Sci. USA*. 2008; 105:9337–9342. [PubMed: 18599440]
- Raghavan M, et al. Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants. *Biochemistry*. 1995; 34:14649–14657. [PubMed: 7578107]
- Ram S, et al. High accuracy 3D quantum dot tracking with multifocal plane microscopy for the study of fast intracellular dynamics in live cells. *Biophys. J*. 2008; 95:6025–6043. [PubMed: 18835896]
- Rath T, et al. The immunologic functions of the neonatal Fc receptor for IgG. *J. Clin. Immunol*. 2013; 33(Suppl 1):S9–S17. [PubMed: 22948741]
- Rehlaender BN, Cho MJ. Antibodies as carrier proteins. *Pharm. Res*. 1998; 15:1652–1656. [PubMed: 9833983]
- Robbie GJ, et al. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. *Antimicrob. Agents Chemother*. 2013; 57:6147–6153. [PubMed: 24080653]
- Rodewald R. pH-dependent binding of immunoglobulins to intestinal cells of the neonatal rat. *J. Cell Biol*. 1976; 71:666–669. [PubMed: 11223]
- Rodewald R, Abrahamson DR. Receptor-mediated transport of IgG across the intestinal epithelium of the neonatal rat. *Ciba. Found. Symp*. 1982:209–232. [PubMed: 6295720]
- Rodewald R, Kraehenbuhl JP. Receptor-mediated transport of IgG. *J. Cell Biol*. 1984; 99:159s–164s. [PubMed: 6235233]
- Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. *Nat. Rev. Immunol*. 2007; 7:715–725. [PubMed: 17703228]
- Rowinsky EK, et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. *J. Clin. Oncol*. 2004; 22:3003–3015. [PubMed: 15210739]

- Sand KM, et al. Dissection of the neonatal Fc receptor (FcRn)-albumin interface using mutagenesis and anti-FcRn albumin-blocking antibodies. *J. Biol. Chem.* 2014; 289:17228–17239. [PubMed: 24764301]
- Sarkar CA, et al. Rational cytokine design for increased lifetime and enhanced potency using pH-activated "histidine switching". *Nat. Biotechnol.* 2002; 20:908–913. [PubMed: 12161759]
- Schlachetzki F, et al. Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier. *J. Neurochem.* 2002; 81:203–206. [PubMed: 12067234]
- Schnulle PM, Hurley WL. Sequence and expression of the FcRn in the porcine mammary gland. *Vet. Immunol. Immunopathol.* 2003; 91:227–231. [PubMed: 12586485]
- Shields RL, et al. High resolution mapping of the binding site on human IgG1 for Fc γ RI, Fc γ RII, Fc γ RIII, and FcRn and design of IgG1 variants with improved binding to the Fc γ R. *J. Biol. Chem.* 2001; 276:6591–6604. [PubMed: 11096108]
- Simister NE, Mostov KE. An Fc receptor structurally related to MHC class I antigens. *Nature.* 1989; 337:184–187. [PubMed: 2911353]
- Simister NE, Rees AR. Isolation and characterization of an Fc receptor from neonatal rat small intestine. *Eur. J. Immunol.* 1985; 15:733–738. [PubMed: 2988974]
- Spiekermann GM, et al. Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung. *J. Exp. Med.* 2002; 196:303–310. [PubMed: 12163559]
- Stapleton NM, et al. Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. *Nat. Commun.* 2011; 2:599. [PubMed: 22186895]
- Story CM, et al. A major histocompatibility complex class I-like Fc receptor cloned from human placenta: possible role in transfer of immunoglobulin G from mother to fetus. *J. Exp. Med.* 1994; 180:2377–2381. [PubMed: 7964511]
- Strauch EM, et al. Computational design of a pH-sensitive IgG binding protein. *Proc. Natl. Acad. Sci. USA.* 2014; 111:675–680. [PubMed: 24381156]
- Suzuki T, et al. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. *J. Immunol.* 2010; 184:1968–1976. [PubMed: 20083659]
- Swiercz R, et al. Use of Fc-engineered antibodies as clearing agents to increase contrast during PET. *J. Nucl. Med.* 2014; 55:1204–1207. [PubMed: 24868106]
- Tabrizi MA, et al. Elimination mechanisms of therapeutic monoclonal antibodies. *Drug. Discov. Today.* 2006; 11:81–88. [PubMed: 16478695]
- Trombetta ES, Mellman I. Cell biology of antigen processing in vitro and in vivo. *Annu. Rev. Immunol.* 2005; 23:975–1028. [PubMed: 15771591]
- Tzaban S, et al. The recycling and transcytotic pathways for IgG transport by FcRn are distinct and display an inherent polarity. *J. Cell Biol.* 2009; 185:673–684. [PubMed: 19451275]
- Vaccaro C, et al. Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies. *Proc. Natl. Acad. Sci. USA.* 2006; 103:18709–18714. [PubMed: 17116867]
- Vaccaro C, et al. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. *Nat. Biotechnol.* 2005; 23:1283–1288. [PubMed: 16186811]
- Vaughn DE, et al. Identification of critical IgG binding epitopes on the neonatal Fc receptor. *J. Mol. Biol.* 1997; 274:597–607. [PubMed: 9417938]
- Vidarsson G, et al. FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis. *Blood.* 2006; 108:3573–3579. [PubMed: 16849638]
- Vieira P, Rajewsky K. The half-lives of serum immunoglobulins in adult mice. *Eur. J. Immunol.* 1988; 18:313–316. [PubMed: 3350037]
- Wallace KH, Rees AR. Studies on the immunoglobulin-G Fc-fragment receptor from neonatal rat small intestine. *Biochem. J.* 1980; 188:9–16. [PubMed: 7406892]

- Wang W, et al. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences. *Drug. Metab. Dispos.* 2011a; 39:1469–1477. [PubMed: 21610128]
- Wang W, et al. Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies. *Mol. Immunol.* 2011b; 48:860–866. [PubMed: 21256596]
- Wang W, et al. Monoclonal antibody pharmacokinetics and pharmacodynamics. *Clin. Pharmacol. Ther.* 2008; 84:548–558. [PubMed: 18784655]
- Wang Z, et al. Discovery and structure-activity relationships of small molecules that block the human immunoglobulin G-human neonatal Fc receptor (hIgG-hFcRn) protein-protein interaction. *Bioorg. Med. Chem. Lett.* 2013; 23:1253–1256. [PubMed: 23375228]
- Ward ES, Ober RJ. Multitasking by exploitation of intracellular transport functions: the many faces of FcRn. *Adv. Immunol.* 2009; 103:77–115. [PubMed: 19755184]
- Ward ES, et al. Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans. *Int. Immunol.* 2003; 15:187–195. [PubMed: 12578848]
- Weflen AW, et al. Multivalent immune complexes divert FcRn to lysosomes by exclusion from recycling sorting tubules. *Mol. Biol. Cell.* 2013; 24:2398–2405. [PubMed: 23741050]
- West AP Jr, Bjorkman PJ. Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor. *Biochemistry.* 2000; 39:9698–9708. [PubMed: 10933786]
- Wilson D, Taura T. Modified antibody with improved half-life. 2013 Office of the U. S. patent and trademark, application number 13/996,733.
- Wu AM. Engineered antibodies for molecular imaging of cancer. *Methods.* 2014; 65:139–147. [PubMed: 24091005]
- Yeung YA, et al. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. *J. Immunol.* 2009; 182:7663–7671. [PubMed: 19494290]
- Yoshida M, et al. Neonatal Fc receptor for IgG regulates mucosal immune responses to luminal bacteria. *J. Clin. Invest.* 2006a; 116:2142–2151. [PubMed: 16841095]
- Yoshida M, et al. IgG transport across mucosal barriers by neonatal Fc receptor for IgG and mucosal immunity. *Springer Semin. Immunopathol.* 2006b; 28:397–403. [PubMed: 17051393]
- Zalevsky J, et al. Enhanced antibody half-life improves in vivo activity. *Nat. Biotechnol.* 2010; 28:157–159. [PubMed: 20081867]
- Zareba KM. Eculizumab: A novel therapy for paroxysmal nocturnal hemoglobinuria. *Drugs Today (Barc).* 2007; 43:539–546. [PubMed: 17925885]
- Zhang Y, Pardridge WM. Mediated efflux of IgG molecules from brain to blood across the blood-brain barrier. *J. Neuroimmunol.* 2001; 114:168–172. [PubMed: 11240028]
- Zhou J, et al. Generation of mutated variants of the human form of the MHC class I-related receptor, FcRn, with increased affinity for mouse immunoglobulin G. *J. Mol. Biol.* 2003; 332:901–913. [PubMed: 12972260]
- Zhou J, et al. Conferring the binding properties of the mouse MHC class I-related receptor, FcRn, onto the human ortholog by sequential rounds of site-directed mutagenesis. *J. Mol. Biol.* 2005; 345:1071–1081. [PubMed: 15644205]
- Zhu X, et al. MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells. *J. Immunol.* 2001; 166:3266–3276. [PubMed: 11207281]

Highlights

- Multiple factors can impact the in vivo pharmacokinetics of an IgG
- Targeting FcRn with inhibitors reduces the levels of circulating IgG
- The engineering of antibody-antigen interactions can enhance the clearance of antigen
- Subcellular trafficking analyses can inform the in vivo behavior of engineered IgGs

Fig. 1. Schematic representation of the different subcellular trafficking pathways taken by FcRn-positive TCs in endothelial cells. For further details, see Gan et al., (2013).

Fig. 2.

Three dimensional structure of the FcRn:Fc-YTE complex (Oganesyan et al., 2014). The X-ray crystallographic structure of the FcRn:Fc-YTE complex is represented as a ribbon diagram with the C α chains of FcRn, β_2 -microglobulin and Fc-YTE colored in green, cyan and blue, respectively. The inset displays an enlarged view of the residues at the interface of the FcRn:Fc-YTE interaction. Salt bridges and hydrogen bonds between the indicated residues of FcRn and Fc-YTE are identified with a cutoff distance of 3.6 Å and are displayed using dotted yellow lines. Fc-YTE residues (Ile253, His310 and His435) playing a crucial role in binding to FcRn are shown in purple and the altered residues that constitute the YTE mutant (Tyr252, Thr254 and Glu256) resulting in affinity enhancement to FcRn at acidic pH are shown in red.

Fig. 3. Schematic representation of the effect of FcRn inhibition by an Abdeg on the subcellular trafficking of IgG. In the absence of inhibition, FcRn:IgG complexes are efficiently recycled and IgG is exocytosed (left panel). In the presence of an Abdeg, which binds to FcRn with increased affinity at pH 6.0-7.4, the interaction of wild type IgG with FcRn in endosomes is blocked (right panel). Consequently, increased levels of IgG enter lysosomes and are degraded.

Fig. 4.

Schematic representation showing how the pH dependent binding of an antibody to a soluble antigen (higher affinity at pH 7.4 than at pH 6.0) increases antigen degradation. Antigen in complex with the pH-independent antibody is taken up into the cell and sorted to recycling TCs through binding to FcRn (left panel). The antigen:pH-independent antibody complex is exocytosed at the cell membrane. By contrast, pH-dependent antibodies dissociate from antigen in early endosomes, resulting in lysosomal delivery of the antigen (right panel). The pH-dependent antibody is recycled by FcRn for re-use.

Fig. 5.

Fluorescence microscopy analyses of the endosomal trafficking behavior of antigen (IL-6) in the presence of antibodies that differ in their pH dependence for binding to antigen. Panels present representative images of endothelial cells (HMEC-1) co-transfected with FcRn-GFP and human β_2 -microglobulin. Following transfection, cells were pulsed with antigen:pH-independent antibody complexes (left panels) or antigen:pH-dependent antibody complexes (right panels). Whole cell images are shown in the upper panels, with expansions of cropped regions to present individual endosomes. For the pH-independent antibody, antigen (IL-6), FcRn and IgG are colocalized on the limiting membrane of the endosome (lower left panels). By contrast, antigen dissociates into the endosomal vacuole in the presence of the pH-dependent antibody (lower right panels). In the expanded images, individual fluorophores are represented in black and white whereas for the overlays, antigen (Alexa 555), FcRn (GFP) and IgG (Alexa 647) are pseudocolored red, green and blue respectively. Background-subtracted fluorescence intensities along the dotted lines in the overlays are shown in the fluorescence intensity plots. The scale bars for the complete cell images and the cropped endosomes represent 4 and 0.5 μm , respectively.

Table I

Properties of half-life extended antibodies

Mutations	IgG species (Isotype)	FcRn species	Fold increase in affinity at pH 6.0 ¹	Species /strains for half-life analysis	Fold increase of half-life	References
T252L/T254S/T256F	Mouse IgG1	Mouse	~ 3.5	Mice	~ 1.6	(Ghetie et al., 1997)
M252Y/S254T/T256E	Human IgG1	Cynomolgus monkey	~ 9	Cynomolgus monkey	~ 3.7	(Dall'Acqua et al., 2006b)
	Human IgG1	Human	~ 11	Human	~ 3.5 ⁵	(Dall'Acqua et al., 2006b; Robbie et al., 2013)
	Human IgG1	Human	~ 1.9	Human FcRn transgenic mice	~ 2.7	(Monnet et al., 2014)
	Human IgG4	Human	~ 4.7 ²	Human FcRn transgenic mice	~ 1.7	(Wilson and Taura, 2013)
M252Y/S254T/T256E/S228P	Human IgG4	Human	~ 4.7 ²	Human FcRn transgenic mice	~ 2.9	
Y31-M252Y/S254T/T256E	Human IgG1	Human	~ 25.5	Human FcRn transgenic mice	5	(Borrok et al., 2014)
	Human IgG1	Human	~ 25.5	Cynomolgus monkey	~ 1.8	
T250Q/M428L	Human IgG2	Human/Rhesus monkey	~ 28 ³	Rhesus monkey	~ 1.8	(Hinton et al., 2004)
	Human IgG1	Human/Rhesus monkey	~ 29 ³ (Human) / 37 ³ (Rhesus)	Rhesus monkey	~ 2.5	(Hinton et al., 2006)
	Human IgG4	Human	49 ³	-	-	
	Human IgG4	Human	~ 10.7 – 115 ⁴	Cynomolgus monkey	~ 0.86 – 2.6	(Datta-Mannan et al., 2012a)
N434A	Human IgG1	Human	1.6 ³	Human FcRn transgenic mice	~ 1.6	(Petkova et al., 2006)
	Human IgG1	Human	~ 3	Cynomolgus monkey	~ 2.3	(Yeung et al., 2009)
T307/E380A/N434A	Human IgG1	Human	3.3 ³	Human FcRn transgenic mice	~ 1.5	(Petkova et al., 2006)
M428L/N434S	Human IgG1	Human	11	Cynomolgus monkey	3.2	(Zalevsky et al., 2010)
V308P	Human IgG4	Cynomolgus monkey	~ 43.3 – 390 ⁴	Cynomolgus monkey	~ 1.9 – 3.2	(Datta-Mannan et al., 2012a)
N315D/A330V/N361D/A378V/N434Y	Human IgG1	Human	7.4	Human FcRn transgenic mice	2.3	(Monnet et al., 2014)
E294D/T307P/N434Y			5.2		2.8	

Mutations	IgG species (Isotype)	FcRn species	Fold increase in affinity at pH 6.0 ¹	Species /strains for half-life analysis	Fold increase of half-life	References
V259I/N315D/N434Y			6.1		2.3	
T307A/N315D/A330V/E382V/N389T/N434Y			4.2		2.3	

¹ Determined by surface plasmon resonance unless otherwise noted.

² Determined by ELISA-based assay.

³ Determined by cell-based assay.

⁴ Measured for five different antibodies with varying antigen specificities.

⁵ For injected dose of 0.3 mg/kg.